ROSELAND, N.J., May 13, 2013 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2013 on Wednesday, May 15, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the Company's web site at: www.emisphere.com . The live conference call dial-in number is 1(877) 303-9483 (United States and Canada) or 1(760) 666-3584 (International). In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning at 1:00 PM ET through midnight on May 29, 2013 by calling 1(855) 859-2056 (United States and Canada) or 1(404) 537-3406 (International). The conference replay PIN is 70998738.
About Emisphere Technologies, Inc.Emisphere is a biopharmaceutical company that focuses on developing and commercializing a unique and improved delivery of pharmaceutical compounds, medical foods and dietary supplements using its Eligen ® Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen ® Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The Company's strategy is to reemphasize the commercialization of Oral Eligen ® B12, build new high-value partnerships, evaluate new Medical Foods commercial opportunities, and promote new uses for the Eligen ® Technology. The Company's website is: www.emisphere.com.
CONTACT: Alan L. Rubino, CEO 973.532.8100 or email@example.com Michael R. Garone, CFO 973.532.8005 or firstname.lastname@example.org
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV